共 50 条
- [1] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance TherapyBLOOD, 2020, 136Kaufman, Jonathan L.Laubach, Jacob P.Sborov, DouglasReeves, BrandiRodriguez, CesarChari, AjaiSilbermann, Rebecca W.Costa, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Holstein, Sara A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Lutska, YanaBobba, PadmaPei, HuilingUkropec, JonVermeulen, JessicaLin, Thomas S.Richardson, Paul G.Voorhees, Peter M.
- [2] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFINCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156Nooka, AjayKaufman, JonathanRodriguez, CesarJakubowiak, AndrzejEfebera, YvonneReeves, BrandiWildes, TanyaHolstein, SarahAnderson, LarryBadros, AshrafShune, LeylaChari, AjaiPei, HuilingCortoos, AnnelorePatel, SharmilaLin, ThomasUsmani, SaadRichardson, PaulVoorhees, Peter
- [3] Daratumumab (DARA) plus Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFINCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S308 - S309Nooka, Ajay K.Kaufman, Jonathan L.Rodriguez, CesarJakubowiak, AndrzejShune, LeylaBadros, AshrafChari, AjaiRichardson, Paul G.Pei, HuilingUkropec, JonVermeulen, JessicaHoehn, DanielaLin, Thomas S.Voorhees, Peter M.
- [4] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of GriffinBLOOD, 2021, 138Anderson, Larry D., Jr.Kaufman, Jonathan L.Laubach, Jacob P.Sborov, Douglas W.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, Rebecca W.Costa, Luciano J.Nathwani, NityaShah, NinaBumma, NareshHolstein, Sarah A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Pei, HuilingCortoos, AnnelorePatel, SharmilaBartlett, J. BlakeVermeulen, JessicaLin, Thomas S.Voorhees, Peter M.Richardson, Paul G.
- [5] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of GriffinBLOOD, 2020, 136Voorhees, Peter M.Rodriguez, CesarReeves, BrandiNathwani, NityaCosta, Luciano J.Lutska, YanaBobba, PadmaHoehn, DanielaPei, HuilingUkropec, JonQi, MingLin, Thomas S.Richardson, Paul G.
- [6] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study UpdateBLOOD, 2019, 134Voorhees, Peter M.Kaufman, Jonathan L.Laubach, Jacob P.Sborov, Douglas W.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, Rebecca W.Costa, Luciano J.Anderson, Larry D.Nathwani, NityaShah, Nina D.Efebera, Yvonne A.Costello, Caitlin L.Jakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Murphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, Jessicade Boer, CarlaHoehn, DanielaLin, Thomas S.Richardson, Paul G.
- [7] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFINBLOOD CANCER JOURNAL, 2022, 12 (04)Nooka, Ajay K.Kaufman, Jonathan L.Rodriguez, CesarJakubowiak, AndrzejEfebera, YvonneReeves, BrandiWildes, TanyaHolstein, Sarah A.Anderson, Larry D., Jr.Badros, AshrafShune, LeylaChari, AjaiPei, HuilingCortoos, AnnelorePatel, SharmilaBartlett, J. BlakeVermeulen, JessicaLin, Thomas S.Richardson, Paul G.Voorhees, Peter
- [8] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFINBlood Cancer Journal, 12Ajay K. NookaJonathan L. KaufmanCesar RodriguezAndrzej JakubowiakYvonne EfeberaBrandi ReevesTanya WildesSarah A. HolsteinLarry D. AndersonAshraf BadrosLeyla ShuneAjai ChariHuiling PeiAnnelore CortoosSharmila PatelJ. Blake BartlettJessica VermeulenThomas S. LinPaul G. RichardsonPeter Voorhees
- [9] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant SubgroupsBLOOD, 2022, 140 : 7278 - 7281Chari, AjaiKaufman, Jonathan L.Laubach, Jacob P.Sborov, Douglas W.Reeves, BrandiRodriguez, CesarSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaBumma, NareshHolstein, Sarah A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Pei, HuilingCortoos, AnnelorePatel, SharmilaLin, Thomas S.Richardson, Paul G.Usmani, SaadVoorhees, Peter M.
- [10] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialBLOOD, 2020, 136 (08) : 936 - 945Voorhees, Peter M.Kaufman, Jonathan L.Laubach, JacobSborov, Douglas W.Reeves, BrandiRodriguez, CesarChari, AjaiSilbermann, RebeccaCosta, Luciano J.Anderson, Larry D., Jr.Nathwani, NityaShah, NinaEfebera, Yvonne A.Holstein, Sarah A.Costello, CaitlinJakubowiak, AndrzejWildes, Tanya M.Orlowski, Robert Z.Shain, Kenneth H.Cowan, Andrew J.Murphy, SeanLutska, YanaPei, HuilingUkropec, JonVermeulen, Jessicade Boer, CarlaHoehn, DanielaLin, Thomas S.Richardson, Paul G.